Mycotopia Therapies Inc
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
AIBTStored price and day change unavailable
Contents
Item 1. Financial Statements
| MYCOTOPIA THERAPIES, INC | ||
|---|---|---|
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||
| AS OF MARCH 31, 2024 (UNAUDITED) AND DECEMBER 31, 2023 | ||
| March 31, | December 31, | |
| 2024 | 2023 | |
| (unaudited) | ||
| ASSETS | ||
| CURRENT ASSETS: | ||
| Cash | $370,425 | $279,134 |
| Prepaid expenses | 500 | - |
| Total Current Assets | 370,925 | 279,134 |
| NON-CURRENT ASSETS: | ||
| Property and equipment, net | 249 | 498 |
| Intangible assets, net | 1,773,723 | 1,939,781 |
| TOTAL ASSETS | $2,144,897 | $2,219,413 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| CURRENT LIABILITIES: | ||
| Accounts payable and accrued expenses | $390,714 | $341,358 |
| Accrued interest | 295,435 | 239,714 |
| Accrued expenses – related party | 648,000 | 576,000 |
| Convertible note payable, net of debt discount | 1,100,000 | 1,090,651 |
| Notes payable – related party | 165,000 | - |
| Shares to be issued | 2,000,000 | 2,000,000 |
| TOTAL LIABILITIES | 4,599,148 | 4,247,723 |
| Commitments and contingencies (Note 9 – Commitments and Contingencies) | - | - |
| MEZZANINE EQUITY | ||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively; liquidation preference of $0 and $0, respectively | - | - |
| STOCKHOLDERS’ DEFICIT | ||
| Common stock, $0.001 par value; 100,000,000 shares authorized, 14,896,791 shares issued and outstanding as of March 31, 2024, and December 31, 2023, respectively | 14,897 | 14,897 |
| Additional paid in capital | 6,917,774 | 6,917,774 |
| Accumulated deficit | (9,386,923) | (8,960,981) |
| TOTAL STOCKHOLDERS’ DEFICIT | (2,454,252) | (2,028,310) |
| TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT | $2,144,897 | $2,219,413 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.